stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Total debt
IDEAYA Biosciences, Inc.'s total debt at the end of fiscal 2022 was $3.5M, down 32.8% from $5.2M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $2.1M. Over the past ten years it has ranged from $3.2M (fiscal 2017) to $6.8M (fiscal 2019); the current reading is higher than 40% of that period. IDEAYA Biosciences, Inc. ranks 339th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $3.5M | (32.79%) |
| FY2021 | $5.2M | (22.94%) |
| FY2020 | $6.7M | (0.72%) |
| FY2019 | $6.8M | 111.16% |
| FY2017 | $3.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $2.1M | (18.47%) |
| Jun 2023 | $2.6M | (15.14%) |
| Mar 2023 | $3.0M | (12.95%) |
| Dec 2022 | $3.5M | (11.26%) |
| 14 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. compare | $753.2M |
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| BEAM Beam Therapeutics Inc. compare | $100.4M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $72.9M |
| DNLI Denali Therapeutics Inc. compare | $5.4M |
| IDYA IDEAYA Biosciences, Inc. | $2.1M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement